Retatrutide 10mg Vial Lab Results — HPLC, Endotoxin & TFA Verification

Batch RET-20-V-2604-001 is the shared lot behind both the 10mg and 40mg vial formats, so the Janoshik workup is the same for both SKUs. The panel covers four distinct measurements, each on a separate certificate.

HPLC purity (reverse-phase, C18). The retatrutide fraction is separated from peptide-related impurities — truncated sequences, deletion variants, synthesis byproducts — on a C18 stationary phase, then quantified against the reference retention time for the parent peptide (LY-3437943, CAS 2381089-83-2). The reported 99.741% figure is the area-under-the-curve percentage for the parent peak, normalised against the sum of all peptide-related peaks. Assay measured 20.92 mg retatrutide per vial of fill weight, confirming the labelled quantity.

Heavy metals (ICP-MS). The four heavy-metal contaminants of pharmacopoeial interest — arsenic, cadmium, lead, mercury — were each measured by ICP-MS and reported as not detected at the relevant limits of quantification. This panel speaks to the upstream synthesis and the dry-fill process; on a lyophilized vial, any heavy-metal trace is concentrated rather than diluted, which is why the test matters more on the vial format than on a pre-formulated pen.

Residual TFA. Trifluoroacetic acid is a common counter-ion in solid-phase peptide synthesis and a frequent residual on insufficiently exchanged peptide lots. Janoshik measured residual TFA and reported it as not detected. For triple-agonist work where receptor binding assays are downstream, removing TFA matters because it can interfere with cell-based readouts.

Bacterial endotoxin (LAL). The Limulus Amebocyte Lysate (LAL) test quantifies bacterial endotoxin — lipopolysaccharide fragments that can persist through synthesis and fill steps. RET-20-V-2604-001 measured 1.449 EU/Vial. Endotoxin is the panel most directly relevant to in-vitro cell work that wants to control for confounding immune signalling; publishing the number on a research-use vial is unusual and is what makes the vial line the documentation-first option in the Remy range.

Retatrutide is a triple-receptor agonist engaging GIP, GLP-1, and glucagon receptors with a single molecule. Triple-agonist potency is highly sensitive to sequence integrity: any truncation or deletion variant alters receptor binding for at least one of the three pathways, which makes HPLC purity verification meaningful, not cosmetic. At 99.741% HPLC, RET-20-V-2604-001 sits in the same band as the rest of the Remy Retatrutide line (30mg pen 99.262%, 20mg pen 99.841%) — inter-batch variation of 0.1–0.6% is normal and reflects analytical precision rather than systematic differences in synthesis.

The 10mg vial is the smaller-quantity format in the vial line and suits shorter or smaller-N research protocols where the full 40mg bulk vial would be larger than the study requires. The HPLC number is what underwrites in-vitro work that compares results to published Eli Lilly trial data on reference-grade material; the heavy metals, residual TFA, and bacterial endotoxin panels speak to the additional confounders that matter in a dry-fill lyophilized format where the dissolved-in-cartridge assumption of the pen line does not apply.